Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Patel CG, Kornhauser D, Vachharajani N, Komoroski B, Brenner E, Handschuh del Corral M, Li L, Boulton DW. Patel CG, et al. Among authors: kornhauser d. Diabetes Obes Metab. 2011 Jul;13(7):604-14. doi: 10.1111/j.1463-1326.2011.01381.x. Diabetes Obes Metab. 2011. PMID: 21332626 Clinical Trial.
An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
Findling RL, Kauffman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, Kornhauser DM, Vachharajani NN, Assuncao-Talbott S, Mallikaarjun S, Iwamoto T, McQuade RD, Boulton DW, Blumer J. Findling RL, et al. Among authors: kornhauser dm. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):431-9. doi: 10.1089/cap.2008.0111. J Child Adolesc Psychopharmacol. 2009. PMID: 19702495
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Pieniaszek HJ Jr, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM. Pieniaszek HJ Jr, et al. J Clin Pharmacol. 2002 Jul;42(7):738-53. doi: 10.1177/009127002401102687. J Clin Pharmacol. 2002. PMID: 12092741 Clinical Trial.
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang CH, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Hodge CN, et al. Lam PY, et al. Among authors: kornhauser dm. J Med Chem. 1996 Aug 30;39(18):3514-25. doi: 10.1021/jm9602571. J Med Chem. 1996. PMID: 8784449
55 results